Kayentis has announced a new executive appointment of Guy Maestre as Vice President U.S. Operations.
Kayentis, a global provider of digital pen and paper technology
and the unique provider of “paper based e-trial” solutions, today announced a new executive appointment of Guy Maestre as Vice President U.S. Operations, therefore continuing and strengthening its expansion in North America.
Philadelphia, PA / Gif sur Yvette, France — December 4th, 2008
Kayentis, a global leader of digital pen and paper technology, is the unique provider of “paper based e-trials” solution for the Life Sciences industry, offering the easiest data collection method possible for both patients and physicians (pen & paper) combined with all the benefits of electronic data management (accurate timestamps, audit trail functionalities, real-time access, alerts, etc.). In order to continue strengthening its expansion in North America, Kayentis today announced a key appointment and welcomes Guy Maestre to the newly created position of Vice President U.S. Operations effective October 6th, 2008.
Mr. Maestre is a highly recognized professional with over 20 years of biopharmaceutical industry experience with an emphasis on general management, as well as the development and marketing of new drugs on a global basis. Most recently he was
Chief Executive Officer
at PhenoTech Inc., a privately held biopharmaceutical company based in Philadelphia specialized in the discovery, development and commercialization of innovative diagnostic products used in blood banks. Prior to this, Mr. Maestre served as President and CEO of Novactyl, an early stage biotech company developing various anti-infective products where he led the company through successful funding, licensing and development activities. Other prior functions include working at Wyeth and G. D. Searle & Co.
Philippe Berna, Kayentis CEO, commented:
“Developing our presence in the US is a normal step to answer our customers’ needs and better serve them, by offering solutions which cover all their needs at each stage of the drug life cycle :
R&D, Pre-Clinical, Clinical, Post-Market and Sales. We are delighted to appoint someone with Guy’s experience and background to this position. This addition reflects very well our commitment to maximize the potential of our US operations. It answers perfectly our desire to continue expanding the growing interest Kayentis solutions has in the US”
.
“Kayentis has developed Clin’Form®
, a very innovative solution for the data capture of Clinical Report Forms and Patient Diaries, successfully implemented in more than 40 countries for 10 000 users (patients, physicians and CRAs)
,” said Guy Maestre. “
Clin’Form® combines the simplicity of traditional pen and paper data capture with the sophistication of Electronic Data Capture (EDC) treatment of the information. This approach provides significant benefits to the biopharmaceutical industry, the physicians and the patients for the implementation of clinical trials. I am very excited to be joining Kayentis to help build our North American operations and to promote this innovative solution to the medical community
.”
Mr. Maestre has an MBA from ESSEC (Ecole Supérieure des Sciences Economiques et Commerciales), has graduated from IPIM, (the Institut de Pharmacie Industrielle) in France and has received his pharmacist degree from the “Université de Pharmacie” in Montpellier, France.
ABOUT KAYENTIS
Kayentis is the leading provider of Digital Pen & Paper (DPP) solutions for the clinical trial industry. Built on the Forms Automation System (FAS) architecture, the Clin’Form® solution allows for all data written using a digital pen and paper, enabling Anoto functionality, to be recorded in an information system and shared via a secure web portal. This cutting-edge solution combines the ease of use of paper with the high technology tools offered by the digital world.
Kayentis is HP Solution Business Partner and Anoto Platinum Partner.
To discover more about this unique solution please visit www.kayentis.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.